nVision Medical
→
Boston Scientific
Acquisition · Cash · BSX · announced Apr 16, 2018
Announced
Apr 16, 2018
Closed
Apr 16, 2018
Economics
Cash()
Pre-deal · pre-deal mark: 2018, year precision · Boston Scientific 8-K filing, SEC EDGAR — nVision Medical acquisition
$150M upfront + up to $125M in milestones over 4 years
Target
nVision Medical
Diagnostics · Diagnostic / genomic
HQ San Carlos, CA · Founded 2013
First FDA-cleared device for collecting cells from fallopian tubes — platform for earlier diagnosis of ovarian cancer; $500M near-term market opportunity estimated
- PR Newswire — Boston Scientific press release (Apr 16, 2018)
- MassDevice deal coverage ($275M total)
Acquirer
Boston Scientific (BSX)
Diagnostics
HQ Marlborough, MA
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
First FDA-cleared fallopian tube cell collection device — platform for ovarian cancer early diagnosis; estimated $500M near-term market expanding to $2B
Evidence ladder
Secondary (press / IR)
PR Newswire — Boston Scientific press release (Apr 16, 2018)
Tertiary (trade / analyst)
MassDevice deal coverage
Primary (regulatory / filing)
SEC EDGAR 8-K https://www.sec.gov/Archives/edgar/data/885725/000088572518000019/q12018earningsrelease.htm
Open source
Limitations
- $150M upfront + up to $125M in milestones over 4 years
- Pre-deal valuation sourced from: Boston Scientific 8-K filing, SEC EDGAR — nVision Medical acquisition. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Diagnostics
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Vs this deal | ||||
|---|---|---|---|---|
| Alere | Abbott Laboratories | Feb 1, 2016 | ||
| Thrive Earlier Detection | Exact Sciences | Oct 27, 2020 | ||
| Igenomix | Vitrolife | Jul 8, 2021 | ||
| EUROIMMUN | PerkinElmer (Revvity) | Jun 16, 2017 |
Other verified deals by Boston Scientific
Acquirer program history not already listed as a valuation peer or adjacency row.
No further verified deals
Other verified transactions by Boston Scientific are already listed above, or none are in the dataset.
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — nVision Medical (Diagnostics). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v11 · updated 2026-10-19 · 3 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.